Outcomes and Computed Tomography Scan Follow-Up of Bioresorbable Vascular Scaffold for the Percutaneous Treatment of Chronic Total Coronary Artery Occlusion - 13/05/15
, Manuel Pan, MD, PhD a, Miguel Romero, MD, PhD a, Javier Suárez de Lezo, MD, PhD a, Francisco Mazuelos, MD, PhD a, José Segura, MD, PhD a, Simona Espejo, MD b, Carmen Morenate, MD a, Marta Blanco, MD b, Pedro Martín, MD, PhD c, Alfonso Medina, MD, PhD c, José Suárez de Lezo, MD, PhD aAbstract |
Everolimus-eluting bioresorbable vascular scaffold (BVS) implantation in chronic total occlusion (CTO) could provide theoretical advantages at follow-up compared with metallic stents. This study aimed to assess the feasibility of BVS use for the percutaneous treatment of CTO by analyzing clinical outcomes and patency at midterm follow-up. From February 2013 to June 2014, 42 patients with 46 CTOs were treated by BVS implantation. Once the guidewire reached the distal lumen, all the occluded segments were predilated. Postdilation was performed in all patients. A multislice computed tomography was scheduled for all patients at 6 months. The mean age was 58 ± 9 years, 41 (98%) were men and 14 (33%) diabetic. The target vessel was predominantly the left anterior descending artery (22, 48%). According to the Japanese-CTO score, 21 CTOs (46%) were difficult or very difficult. Most cases were treated with an anterograde strategy (34 lesions, 74%). A hybrid procedure with a drug-eluting stent at the distal segment was the applied treatment in 7 CTOs (15%). The mean scaffold length was 43 ± 21 mm. Technical success was achieved in 45 lesions (98%), and 1 patient (2.4%) presented a non-Q periprocedural myocardial infarction. Re-evaluation was obtained in all patients at 6 ± 1 months. Two re-occlusions and a focal restenosis were identified. After 13 ± 5 months of follow-up, there were 2 repeat revascularizations (4.8%). Neither death nor myocardial infarction was documented. In conclusion, BVS for CTO seems to be an interesting strategy with a high rate of technical success and low rate of cardiac events at midterm follow-up in selected patients.
Le texte complet de cet article est disponible en PDF.Plan
| See page 1492 for disclosure information. |
Vol 115 - N° 11
P. 1487-1493 - juin 2015 Retour au numéro
Article précédent
- Meta-Analysis of Randomized Controlled Trials Comparing Multivessel Versus Culprit-Only Revascularization for Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Disease Undergoing Primary Percutaneous Coronary Intervention
- Georges E. El-Hayek, Anthony H. Gershlick, Mun K. Hong, Abel Casso Dominguez, Amerjeet Banning, Arash Ehteshami Afshar, Eyal Herzog, Jacqueline E. Tamis-Holland
- State Mandated Public Reporting and Outcomes of Percutaneous Coronary Intervention in the United States
- Matthew A. Cavender, Karen E. Joynt, Craig S. Parzynski, Frederick S. Resnic, John S. Rumsfeld, Mauro Moscucci, Frederick A. Masoudi, Jeptha P. Curtis, Eric D. Peterson, Hitinder S. Gurm
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?